Hits & misses in treating diabetic complications: part II

Abstract

Last week, Inpharma ® reviewed the use of aldose reductase inhibitors and glycosylation antagonists in the treatment of diabetic complications, as discussed during the 2nd International Conference on ‘Diabetic Complications as Drug Targets’ ^* [ London, UK; May 1996 ]. In this week’s issue, the review continues with one of the recent ‘misses’ of research in this field, levacecarnine [acetyl-L-carnitine; ST-200]. The role of neurotrophins and growth factors in the development of diabetic complications are also reviewed, along with their potential as targets for treatment.